[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"Beijing Sanbo Brain Hospital\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":180},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,7,0,[8,50,77,98,118,137,155],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":19,"targetDuration":22,"studyType":23,"phases":4,"briefSummary":24,"conditions":25,"keywords":29,"overallStatus":37,"whyStopped":4,"lastUpdateSubmitDate":38,"lastUpdatePostDateStruct":39,"startDateStruct":42,"completionDateStruct":44,"leadSponsor":46,"locationsCount":49},"100584813","electroencephalogram-predicts-post-operative-delirium-100584813",false,"NCT06894238","Electroencephalogram Predicts Post-operative Delirium","Frontal-temporal EEG During Anesthesia Recovery Predicts Postoperative Delirium in Neurosurgery: a Single-center, Prospective, Observational Study","EPOD","Inclusion Criteria:\n\n* Age ≥ 18 years\n* Planned elective neurosurgical surgery\n* ASA physical status I-II\n* Signed informed consent\n\nExclusion Criteria:\n\n* Known neurological or psychiatric disorders (e.g., epilepsy, Parkinson's disease)\n* Preoperative cognitive impairment (MMSE score \\\u003C 24)\n* Long-term use of central nervous system drugs (e.g., antidepressants, antipsychotics)\n* Language barriers\n* History of craniotomy within the last 12 months\n* Inability to place frontal-temporal electrodes due to conditions such as frontal skin injury, severe agitation, or a coronal incision for surgery\n* Pregnant or breastfeeding women","ALL","18 Years",{"count":20,"type":21},137,"ESTIMATED","30 Days","OBSERVATIONAL","The goal of this observational study is to investigate the predictive value of sub-hairline electroencephalography (EEG) during anesthesia recovery for postoperative delirium (POD). The main question to be answered is:\n\n* Can sub-hairline EEG measured during anesthesia recovery serve as a reliable predictor of POD? Adult patients undergoing elective craniotomy and admitted to the ICU will be enrolled. Sub-hairline EEG will be monitored until ICU discharge.",[26,27,28],"Neurosurgery","Delirium - Postoperative","Brain Tumor Adult",[30,31,32,33,34,35,36],"Postoperative delirium","electroencephalography","neurosurgical patients","Sub-hairline EEG","Confusion Assessment Method for ICU (CAM-ICU)","Delirium Observation Screening Scale (DOSS)","Fluctuating Mental Status Evaluation (FMSE)","RECRUITING","2025-03-18",{"date":40,"type":41},"2025-03-25","ACTUAL",{"date":43,"type":41},"2025-03-01",{"date":45,"type":21},"2026-05-01",{"name":47,"class":48},"Beijing Sanbo Brain Hospital","OTHER",2,{"id":51,"slug":52,"hasResults":11,"nctId":53,"briefTitle":54,"officialTitle":55,"acronym":4,"eligibilityCriteria":56,"healthyVolunteers":11,"sex":17,"minAge":57,"maxAge":58,"enrollmentInfo":59,"targetDuration":4,"studyType":61,"phases":62,"briefSummary":64,"conditions":65,"keywords":4,"overallStatus":37,"whyStopped":4,"lastUpdateSubmitDate":68,"lastUpdatePostDateStruct":69,"startDateStruct":71,"completionDateStruct":73,"leadSponsor":75,"locationsCount":76},"100460675","phase-2-modified-cv-regimen-in-optic-pathway-glioma-100460675","NCT05278715","Modified CV Regimen in Optic Pathway Glioma","Clinical Study of Modified Carboplatin\u002Fvincristine Chemotherapy Regimen for Visual Function Protection in Children with Optic Pathway Gliomas","Inclusion Criteria:\n\n* Age ≥ 3months and ≤21years;\n* Patients with optic pathway gliomas diagnosed by histopathology or characteristic brain MRI and clinical features;\n* Measurable lesions, surgical resection degree \\\u003C 95% or postoperative residual tumor ≥1.5cm\\^2;\n* KPS score ≥50 (age \\>12 years) or Lansky score ≥50 (age ≤12 years);\n* Clinical symptoms such as decreased visual acuity, visual field defect, optic disc edema, exophthalmia, increased intracranial pressure, diencephalic syndrome, etc;\n* No dysfunction of major organs.\n\nExclusion Criteria:\n\n* MRI examination is not available.\n* Failing to comply with the visual examination.\n* H3K27 mutations, even histopathological grade 1\u002F2.\n* Receiving any other investigational agent.\n* History of allergic reactions attributed to compounds of similar chemical or biologic composition to the drugs used in this study.\n* Patients who have received organ transplants.\n* Patients infected with HIV or treponema pallidum.\n* Suffering from serious cardiovascular disease;T wave inversion or elevation or ST segment changes.\n* Patients who had coagulation disorder and were being treated with thrombolytic or anticoagulant drugs. Patients with significant clinical bleeding symptoms or clear bleeding tendency occurred within 3 months before enrollment, such as gastrointestinal bleeding, hemorrhagic gastric ulcer, gastrointestinal perforation, baseline fecal occult blood ++ or above, intratumoral or intracranial bleeding, or vasculitis, etc. Arteriovenous thrombosis events (such as cerebrovascular accident (including transient ischemic attack, cerebral hemorrhage and cerebral infarction), deep vein thrombosis and pulmonary embolism) occurred within 6 months before enrollment.\n* Pregnant or breastfeeding.\n* Other conditions considered inappropriate by the researcher for inclusion.","3 Months","21 Years",{"count":60,"type":21},75,"INTERVENTIONAL",[63],"PHASE2","Optic pathway glioma (OPG) can result in visual deterioration. Symptomatic patients often report deficits in visual acuity (VA), visual field, visual-evoked potentials (VEPs), strabismus, proptosis, disc swelling, and other visual\u002Fneurological problems. VA itself remains one of the most important outcome measures for OPG patients, with various studies showing strong ties of VA level to overall quality of life and well-being . Maintenance of favorable VA and vision outcomes is of paramount importance in the management of OPG.\n\nIn terms of management of OPG, surgery and radiotherapy are used on a more limited basis because of location of the tumors and risk of secondary tumors, respectively. Tumor stabilization often prioritized, and chemotherapy is considered ideal for tumor stabilization in OPG, but vision is not always retained and may worsen in some cases, partially due to low radiographic efficacy and long time interval to response of the current chemotherapy regimen.\n\nIn the prior study, the investigators modified the traditional carboplatin combined with vincristine regimen by increasing the dose of carboplatin and combining with an anti-angiogenic drug. Of the 15 OPG patients, objective response rate was 80% and the time to response was only 3.3 months. 8 (53%) patients experienced an improvement in visual acuity during therapy and 6 (40%) were stable, which was higher than the historical studies.\n\nThis study was launched to further verify the clinical efficacy of the modified regimen and its effect on visual acuity improvement.",[66,67],"Optic Glioma","Pediatric Brain Tumor, Optic Nerve Glioma","2024-10-09",{"date":70,"type":41},"2024-10-15",{"date":72,"type":41},"2022-04-13",{"date":74,"type":21},"2025-12-31",{"name":47,"class":48},1,{"id":78,"slug":79,"hasResults":11,"nctId":80,"briefTitle":81,"officialTitle":82,"acronym":4,"eligibilityCriteria":83,"healthyVolunteers":84,"sex":17,"minAge":85,"maxAge":58,"enrollmentInfo":86,"targetDuration":4,"studyType":61,"phases":88,"briefSummary":89,"conditions":90,"keywords":4,"overallStatus":37,"whyStopped":4,"lastUpdateSubmitDate":68,"lastUpdatePostDateStruct":92,"startDateStruct":93,"completionDateStruct":95,"leadSponsor":97,"locationsCount":76},"100401013","phase-2-apatinib-combined-with-temozolomide-and-etoposide-capsules-in-the-treatment-of-recurrent-medulloblastoma-in-children-100401013","NCT04501718","Apatinib Combined with Temozolomide and Etoposide Capsules in the Treatment of Recurrent Medulloblastoma in Children","A Single Arm Clinical Phase Ⅱ Study of Apatinib Combined with Temozolomide and Etoposide Capsules in the Treatment of Recurrent Medulloblastoma in Children","Inclusion Criteria:\n\n1. Age 2-21 (at the time of diagnosis), no gender limit.\n2. After biopsy or surgery, the first postoperative pathological diagnosis is medulloblastoma.\n3. The recurrence of the tumor is confirmed by MRI, that is, the diameter of the lesion on the enhanced MRI image is ≥1cm, and ≥2 slices (slice spacing 5mm) are visible; or after another biopsy or surgery, the pathological diagnosis is medulloblastoma.\n4. The time interval from the last radiotherapy is ≥4 weeks.\n5. The time interval from the last chemotherapy is ≥4 weeks, and the patients have fully recovered from the acute toxicity of the last treatment. If you receive nitrosourea chemotherapeutics before enrollment, the interval between enrollment and the last chemotherapy is ≥6 weeks.\n6. The interval between the last biopsy or surgery is ≥2 weeks.\n7. KPS score ≥50 (patient\\> 12 years old), or Lansky score ≥ 50 (patient ≤ 12 years old).\n8. If the patient is taking glucocorticoid therapy, the hormone dosage has stabilized or decreased for at least 1 week before the baseline MRI.\n9. The expected survival time is ≥12 weeks.\n10. The main organ functions are normal, and there is no serious blood, heart, lung, liver, kidney dysfunction and immune deficiency diseases. The laboratory inspection meets the following requirements:\n\n(1) Routine blood examination, which must be met (no blood transfusion within 14 days):\n\n1. HGB≥100g\u002FL;\n2. WBC≥3.0×109\u002FL; NEUT≥1.5×109\u002FL;\n3. PLT ≥100×109\u002FL; (2) The biochemical inspection shall meet the following standards:\n\na. BIL≤1.5 times the upper limit of normal (ULN); b. ALT and AST≤2.0×ULN; c. Serum Cr≤1.5×ULN or endogenous creatinine clearance ≥50ml\u002Fmin (Cockcroft-Gault formula); (3) Occult blood in stool (-); (4) Urine routine is normal, or urine protein \\\u003C(++), or 24-hour urine protein \\\u003C1.0 g; 11. The ECG shows that the heart rate is in the normal range (55-100 beats\u002Fmin), the QT interval is normal or slightly prolonged (QTc\\\u003C480ms), the T wave is normal or low, and the ST segment is normal or non-specific changes.\n\n12\\. The coagulation function is normal, without active bleeding and thrombosis.\n\n1. International standardized ratio INR≤1.5×ULN;\n2. Partial thromboplastin time APTT≤1.5×ULN;\n3. Prothrombin time PT≤1.5ULN. 13. Female patients of childbearing age must undergo a negative pregnancy test (serum or urine) within 7 days before enrollment, and voluntarily use appropriate methods of contraception during the observation period and within 8 weeks after the last administration; male patients of childbearing age should agree to During the observation period and within 8 weeks after the last administration, use appropriate methods of contraception.\n\n   14\\. Patients voluntarily provide 25-30 slices of tumor tissue after the last biopsy or surgery.\n\n   15\\. The patient has normal swallowing function and can swallow capsules. 16. The patient voluntarily joined the study and signed an informed consent form (ICF).\n\n   17\\. Those who are expected to have good compliance can follow up the efficacy and adverse reactions as required by the plan.\n\n   Exclusion Criteria:\n   1. Past application of anti-tumor angiogenesis drugs;\n   2. Those who are known to be allergic to any component of temozolomide, apatinib, and etoposide;\n   3. Are using antiepileptic drugs that induce liver drug enzymes, unless they have been replaced with antiepileptic drugs that are non-hepatic drug enzymes at least 2 weeks away from enrollment;\n   4. Patients with other malignant tumors, unless they have survived without progression for 5 years and the researcher believes that the risk of recurrence is low or patients with carcinoma in situ;\n   5. People with hypertension who cannot be reduced to the normal range after treatment with antihypertensive drugs (systolic blood pressure ≤140 mmHg \u002F diastolic blood pressure ≤ 90 mmHg);\n   6. Suffering from severe cardiovascular disease; T wave inverted or high tip of ECG, ST segment specific changes.\n   7. Urine routine test indicates urine protein ≥(++), or 24-hour urine protein ≥1.0g;\n   8. Abnormal coagulation function (INR\\>1.5 or prothrombin time (PT)\\>ULN+4 seconds or APTT\\>1.5×ULN), have bleeding tendency or are receiving thrombolytic or anticoagulant therapy;\n   9. There are many factors that affect the absorption of oral drugs, such as uncontrollable nausea and vomiting, chronic diarrhea and intestinal obstruction;\n   10. There is an infection that is difficult to control;\n   11. Have had significant clinically significant bleeding symptoms or a clear bleeding tendency within 3 months before enrollment, such as gastrointestinal bleeding, hemorrhagic gastric ulcer, gastrointestinal perforation, fecal occult blood++ and above at baseline, intratumoral or Intracranial hemorrhage, or suffering from vasculitis, etc.;\n   12. Arterial\u002Fvenous thrombosis events that occurred within 6 months before enrollment, such as cerebrovascular accidents (including temporary ischemic attacks, cerebral hemorrhage, cerebral infarction), deep vein thrombosis, and pulmonary embolism;\n   13. Pregnant or breast-feeding women; fertility patients who are unwilling or unable to take effective contraceptive measures;\n   14. Other situations that the researcher thinks are not suitable for inclusion.",true,"2 Years",{"count":87,"type":21},44,[63],"This study is a prospective single-center clinical study, which aims to observe and evaluate the efficacy and safety of apatinib combined with temozolomide and oral etoposide in the treatment of recurrent medulloblastoma in children.",[91],"Recurrent Medulloblastoma",{"date":70,"type":41},{"date":94,"type":41},"2020-10-28",{"date":96,"type":21},"2025-08-31",{"name":47,"class":48},{"id":99,"slug":100,"hasResults":11,"nctId":101,"briefTitle":102,"officialTitle":103,"acronym":4,"eligibilityCriteria":104,"healthyVolunteers":84,"sex":17,"minAge":18,"maxAge":105,"enrollmentInfo":106,"targetDuration":4,"studyType":61,"phases":108,"briefSummary":110,"conditions":111,"keywords":4,"overallStatus":37,"whyStopped":4,"lastUpdateSubmitDate":68,"lastUpdatePostDateStruct":113,"startDateStruct":114,"completionDateStruct":116,"leadSponsor":117,"locationsCount":76},"100401012","apatinib-in-the-treatment-of-recurrent-atypicalmalignant-meningioma-in-adults-100401012","NCT04501705","Apatinib in the Treatment of Recurrent Atypical\u002Fmalignant Meningioma in Adults","Clinical Study of Apatinib in the Treatment of Recurrent Atypical\u002Fmalignant Meningioma in Adults","Inclusion Criteria:\n\n1. Age ≥18 years old (at the time of enrollment), regardless of gender.\n2. The pathological diagnosis of atypical\u002Fmalignant meningioma was clear after biopsy or surgery.\n3. The tumor recurrence is confirmed by MRI, that is, the diameter of the lesion on the enhanced MRI image is ≥1cm, and ≥2 slices (slice interval 5mm) are visible; or after another biopsy or surgery, the pathological diagnosis is atypical\u002Fmalignant meningioma.\n4. Previous surgery and radiotherapy (including conventional radiotherapy or stereotactic radiosurgery treatment) are required. There are no restrictions on whether to receive chemotherapy or the number of times of the above treatments\n5. The time interval from the last radiotherapy is ≥4 weeks.\n6. The time interval from the last chemotherapy is ≥4 weeks, and the patients have fully recovered from the acute toxicity of the last treatment.\n7. The interval between the last biopsy or surgery is ≥2 weeks.\n8. KPS score ≥50 points.\n9. If the patient is on glucocorticoid therapy, the hormone dosage has stabilized or decreased for at least 2 weeks before the baseline MRI.\n10. The expected survival time is ≥12 weeks.\n11. The main organ functions are normal, and there is no serious blood, heart, lung, liver, kidney dysfunction and immune deficiency diseases. The laboratory inspection meets the following requirements:\n\n(1) Routine blood examination, which must be met (no blood transfusion within 14 days):\n\n1. HGB≥100g\u002FL;\n2. WBC≥3.0×109\u002FL; NEUT≥1.5×109\u002FL;\n3. PLT ≥100×109\u002FL; (2) The biochemical inspection shall meet the following standards:\n\na. BIL≤1.5 times the upper limit of normal (ULN); b. ALT and AST≤2.0×ULN; c. Serum Cr≤1.5×ULN or endogenous creatinine clearance ≥50ml\u002Fmin (Cockcroft-Gault formula); (3) Occult blood in stool (-); (4) Urine routine is normal, or urine protein \\\u003C(++), or 24-hour urine protein \\\u003C1.0 g; (5) Left ventricular ejection fraction (LVEF) ≥50%. 12. The coagulation function is normal, without active bleeding and thrombosis.\n\n1. International standardized ratio INR≤1.5×ULN;\n2. Partial thromboplastin time APTT≤1.5×ULN;\n3. Prothrombin time PT≤1.5ULN. 13. Female patients of childbearing age must undergo a negative pregnancy test (serum or urine) within 7 days before enrollment, and voluntarily use appropriate methods of contraception during the observation period and within 8 weeks after the last administration of apatinib mesylate tablets ; Male patients of childbearing age should agree to use appropriate methods of contraception during the observation period and within 8 weeks after the last administration of apatinib mesylate tablets.\n\n   14\\. Patients need to provide 25-30 pieces of tumor tissue slices after the last biopsy or surgery.\n\n   15\\. The patient has normal swallowing function and can swallow the tablet intact.\n\n   16\\. The patient voluntarily joined the study and signed an informed consent form (ICF).\n\n   17\\. The patient is expected to have good compliance and be able to follow up the efficacy and adverse reactions as required by the protocol.\n\n   Exclusion Criteria:\n   1. Past application of anti-tumor angiogenesis drugs;\n   2. Patients diagnosed with neurofibromatosis type 2 and other tumor syndromes;\n   3. People who are known to be allergic to any component of apatinib mesylate;\n   4. Antiepileptic drugs that induce liver enzymes are being used, unless antiepileptic drugs that have been replaced with non-hepatic enzymes are at least 2 weeks away from enrollment;\n   5. Patients with other malignant tumors, unless they have survived for 5 years and the investigator believes that the risk of recurrence is low or patients with carcinoma in situ;\n   6. Patients with hypertension who cannot be reduced to the normal range after treatment with antihypertensive drugs (systolic blood pressure ≤ 140 mmHg \u002F diastolic blood pressure ≤ 90 mmHg);\n   7. Patients with coronary heart disease ≥2 grade, arrhythmia (including QTc prolongation in men\\>450 ms, women\\>470 ms) and cardiac insufficiency;\n   8. Urine routine test indicates urine protein ≥(++), or 24-hour urine protein ≥1.0g;\n   9. Abnormal coagulation function (INR\\>1.5 or prothrombin time (PT)\\>ULN+4 seconds or APTT\\>1.5×ULN), have bleeding tendency or are receiving thrombolytic or anticoagulant therapy;\n   10. There are many factors that affect the absorption of oral drugs, such as uncontrollable nausea and vomiting, chronic diarrhea and intestinal obstruction;\n   11. There is an infection that is difficult to control;\n   12. Those who had significant blood coughing up 2 months before enrollment, or had blood volume of 2.5ml or more per day; had clinically significant bleeding symptoms or had clear bleeding tendency within 3 months before enrollment, such as Gastrointestinal bleeding, hemorrhagic gastric ulcer, gastrointestinal perforation, stool occult blood++ and above at baseline, intratumoral or intracranial hemorrhage, or vasculitis, etc.;\n   13. Arterial\u002Fvenous thrombosis events that occurred within 6 months before enrollment, such as cerebrovascular accidents (including temporary ischemic attacks, cerebral hemorrhage, cerebral infarction), deep vein thrombosis and pulmonary embolism;\n   14. Pregnant or breast-feeding women; fertility patients who are unwilling or unable to take effective contraceptive measures;\n   15. Other situations that the researcher thinks are not suitable for inclusion.","70 Years",{"count":107,"type":21},29,[109],"NA","Apatinib mesylate may be an effective treatment for recurrent atypical\u002Fmalignant meningioma. This prospective clinical study is now planned to verify the effectiveness and safety of apatinib mesylate in the treatment of relapsed atypical\u002Fmalignant meningioma.",[112],"Recurrent Atypical\u002Fmalignant Meningioma",{"date":70,"type":41},{"date":115,"type":41},"2020-08-18",{"date":96,"type":21},{"name":47,"class":48},{"id":119,"slug":120,"hasResults":11,"nctId":121,"briefTitle":122,"officialTitle":123,"acronym":4,"eligibilityCriteria":124,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":105,"enrollmentInfo":125,"targetDuration":4,"studyType":61,"phases":127,"briefSummary":128,"conditions":129,"keywords":4,"overallStatus":37,"whyStopped":4,"lastUpdateSubmitDate":68,"lastUpdatePostDateStruct":132,"startDateStruct":133,"completionDateStruct":135,"leadSponsor":136,"locationsCount":76},"100383080","phase-2-study-of-recombinant-human-endostatin-combined-with-temozolomide-and-irinotecan-in-recurrent-gliomas-100383080","NCT04267978","Study of Recombinant Human Endostatin Combined with Temozolomide and Irinotecan in Recurrent Gliomas","Open-label Prospective Study of Recombinant Human Endostatin Combined with Cytotoxic Chemotherapy Regimen in the Treatment of Recurrent Gliomas","Inclusion Criteria:\n\n1. Age ≥ 18 and ≤70;\n2. Histopathologically-confirmed, supratentorial GBM or lower-grade gliomas (such as oligodendroglioma, astrocytoma, oligoastrocytoma, anaplastic astrocytoma, anaplastic oligodendroglioma or anaplastic oligoastrocytoma);\n3. Recurrence is pathologically confirmed by another biopsy or surgery, which should have been completed at least 2 weeks before enrollment, or confirmed by the MRI according to RANO criteria, at least one bi-dimensionally measurable contrast-enhancing target lesion, with one diameter at least 10 mm, visible on two or more axial slices 5mm apart;\n4. Received standard chemoradiotherapy and at least one cycle of chemotherapy after primary diagnosis;\n5. The time intervals between the last radiotherapy and enrollment are at least 3 months;\n6. The interval form the last chemotherapy to the study enrollment was at least one interval of chemotherapy with recover from the related toxic effects (except for hair loss and pigmentation);\n7. Karnofsky Performance Status ≥ 60;\n8. If the patient is on glucocorticoid therapy, hormone dosage should be stable or decreased at least 5 days before baseline MRI;\n9. If the patient is receiving enzyme-inducing antiepileptic drugs (EIAEDs), the drugs should be replaced with non-EIAEDs for at least 1 weeks away from enrollment;\n10. Estimated survival of at least 12 weeks;\n11. Participants must have adequate organ function as defined by the following criteria (within 7 days before treatment):\n\n    1. Hematology (No transfusion within 14 days):\n\n       * Hemoglobin(HB)≥90g\u002FL;\n\n         * Absolute neutrophil count (ANC)≥1.5×109\u002FL;\n\n           * Platelet (PLT)≥80×109\u002FL.\n    2. Chemistry:\n\n       * Serum bilirubin ≤ 1.5×upper limit of normal (ULN)\n\n         * ALT and AST≤2.5ULN；\n\n           * Serum creatinine ≤1.5ULN or creatinine clearance rate(CCr)≥60ml\u002Fmin；\n    3. ECG: heart rate in the normal range (55-100beats\u002Fmin), normal or slightly prolonged QT interval (QTc\\\u003C480ms), normal or low T wave, normal or non-specific ST segment changes.\n12. Both men and women at the gestational age must agree to take adequate contraceptive measures throughout the study period.\n13. Participants volunteered to participate in the study and signed an informed consent form (ICF)\n\nExclusion Criteria:\n\n1. MRI examination is not available (such as pacemaker, metal denture);\n2. Receiving any other investigational agent.\n3. History of allergic reactions attributed to compounds of similar chemical or biologic composition to the drugs used in this study.\n4. Patients who have received organ transplants.\n5. Patients with HIV or Treponema pallidum infection.\n6. Severe heart disease; ECG shows T wave inversion or elevation or ST segment specific changes.\n7. Having factors that affect oral drug absorption, such as vomiting, diarrhea and intestinal obstruction\n8. There were clinically significant bleeding symptoms or clear bleeding tendency in the first 3 months before enrollment, such as gastrointestinal bleeding, hemorrhagic gastric ulcer, gastrointestinal perforation, baseline fecal occult blood ++ and above, intracranial or intracranial hemorrhage, or vasculitis;\n9. Arteriovenous thrombosis events occurred within 6 months before enrollment, such as cerebrovascular accidents (including temporary ischemic attack, cerebral hemorrhage, cerebral infarction), deep vein thrombosis and pulmonary embolism, etc.;\n10. Having bleeding disorder and are being treated with thrombolytic or anticoagulant drugs.\n11. Other conditions considered inappropriate by the researcher for inclusion.",{"count":126,"type":21},109,[63],"Almost all gliomas relapse. After temozolomide rechallenge or combination with irinotecan, the progression-free survival rate at 6 months (PFS-6%) of recurrent glioblastoma was about 21%. After treatment with irinotecan-based chemotherapy regimen, the PFS-6% of recurrent lower-grade gliomas was 40%. The optimal chemotherapeutics of recurrent gliomas has yet to be determined.\n\nAnti-angiogenesis is a promising therapeutic strategy. Vascular endothelial growth factor-A (VEGF) is the primary driver of angiogenesis in tumors. Bevacizumab, a humanized monoclonal antibody directed against VEGF, is the prototypical anti-angiogenic drug and received accelerated approval of the United States Food and Drug Administration (FDA) for the treatment of recurrent glioblastoma. Bevacizumab inproved the PFS-6% (36%), but had no effect on the overall survival (OS) (9.2 months). Moreover, the effects of bevacizumab are transient and most patients' tumors progress just after a median time of 3-5 months. Recombinant human endostatin (rh-ES) is an endogenous broad-spectrum angiogenesis inhibitor that has been shown to significantly improve therapeutic efficacy when combining with conventional chemotherapy agents in non-small-cell lung cancer, breast cancer and melanoma.\n\nIn our previous study, we retrospectively analyzed the effect and toxicity of rh-ES when combined with temozolomide and irinotecan on adult recurrent disseminated glioblastoma. After combined treatment, PFS-6% was 23.3%; the median PFS and OS were 3.2 and 6.9 months, respectively, which were promising compared with that in other studies. Once patients get radiographic remission in a short time (4 months), they may get a long PFS.The combined regimen did not reduce the sensitivity of tumor to bevacizumab. After tumor progression from the combined chemotherapy, bevacizumab usage could help to prolong the survival time (5.1 months versus 2.4 months). Moreover, the toxicities of the combination therapy in this study were manageable.\n\nOn the basis of prior clinical experience, we carry out this prospective trial to confirm the efficacy and safety of the combination of rh-ES, temozolomide and irinotecan in patients with recurrent gliomas.",[130,131],"Glioblastoma, Recurrent","Lower Grade Glioma, Recurrent",{"date":70,"type":41},{"date":134,"type":41},"2020-02-13",{"date":74,"type":21},{"name":47,"class":48},{"id":138,"slug":139,"hasResults":11,"nctId":140,"briefTitle":141,"officialTitle":142,"acronym":4,"eligibilityCriteria":143,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":144,"targetDuration":4,"studyType":61,"phases":146,"briefSummary":147,"conditions":148,"keywords":4,"overallStatus":37,"whyStopped":4,"lastUpdateSubmitDate":68,"lastUpdatePostDateStruct":150,"startDateStruct":151,"completionDateStruct":152,"leadSponsor":154,"locationsCount":76},"100367880","phase-2-camrelizumab-for-patients-with-recurrent-primary-central-nervous-system-lymphoma-pcnsl-100367880","NCT04070040","Camrelizumab for Patients with Recurrent Primary Central Nervous System Lymphoma (PCNSL)","An Exploratory Study on Camrelizumab（SHR-1210）for Recurrent Primary Central Nervous System Lymphoma (PCNSL)","Inclusion Criteria:\n\n1. The initial diagnosis was primary diffuse large B-cell lymphoma of the central nervous system confirmed by histopathology;\n2. Prior to first-line treatment based on methotrexate (with or without radiotherapy), tumor recurrence was confirmed by MRI;\n3. Measurable focus in MRI (\\>10x10mm);\n4. Aged \\> 18 years;\n5. Life expectancy of at least 12 weeks;\n6. The patient has a Karnofsky performance status of at least 50%;\n7. Main organs function normally, without serious blood, heart, lung, liver, kidney and immune deficiency diseases. Specific assay indicators requirements： White blood cells\\>3.0×10\\^9\u002FL;platelet\\>80×10\\^9\u002FL;hemoglobin\\>10g\u002FdL;serum bilirubin ≤ 1.5×ULN;ALT and AST ≤ 2×ULN;serum creatinine≤1.5mg\u002FdL;\n8. Female subjects of childbearing age must exclude pregnancy and are willing to use a medically approved high-efficiency contraceptive (eg, IUD, contraceptive or condom) during the study period and within 3 months of the last study drug administration;\n9. The subject should be aware of the purpose of the study and the operations required by the study and volunteer to participate in the study before sign the informed consent form;\n\nExclusion Criteria:\n\n1. Concurrent administration of any other antitumor therapy；\n2. Allergic to the ingredients of research drugs；\n3. Has received prior therapy with an anti-PD-1, anti-PD-L1, or anti-PD-L2 agent；\n4. Any active autoimmune diseases or a history of autoimmune diseases (including but not limited to: autoimmune hepatitis, interstitial pneumonia, uveitis, enteritis, hepatitis, pituitary inflammation, vasculitis, nephritis, hyperthyroidism, decreased thyroid function；\n5. Systemic steroid therapy or any other form of immunosuppressive therapy within 7 days prior to the first dose of trial treatment, except for a maximum dose of 4 mg\u002Fday dexamethasone or equivalent doses of other corticosteroids or control of brain edema, which has been stable or decreased for at least 1 week prior to inclusion;\n6. Active infection;\n7. Risk of bleeding;\n8. HIV positivity;\n9. Pregnancy and lactation;",{"count":145,"type":21},21,[63],"This study is intend to improve the objective response rate in treatment of camrelizumab in recurrent primary central nervous system lymphoma patients.",[149],"Primary Central Nervous System Lymphoma",{"date":70,"type":41},{"date":134,"type":41},{"date":153,"type":21},"2024-12-31",{"name":47,"class":48},{"id":156,"slug":157,"hasResults":11,"nctId":158,"briefTitle":159,"officialTitle":160,"acronym":4,"eligibilityCriteria":161,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":162,"targetDuration":4,"studyType":23,"phases":4,"briefSummary":164,"conditions":165,"keywords":168,"overallStatus":37,"whyStopped":4,"lastUpdateSubmitDate":172,"lastUpdatePostDateStruct":173,"startDateStruct":175,"completionDateStruct":177,"leadSponsor":179,"locationsCount":76},"100552982","mechanical-ventilation-on-hippocampus-100552982","NCT06480162","Mechanical Ventilation on Hippocampus","Impact of Mechanical Ventilation on Hippocampal Oscillation and Respiratory-hippocampus Coupling","Inclusion Criteria:\n\n* Age: ≥ 18 years\n* ASA: I - II\n* w\u002F electrode inside hippocampus (≥ 1 contacts)\n* Singed consent form\n\nExclusion Criteria:\n\n* Seizure occurrence ≤ 36 hours before op.\n* Structural brain damage\n* History of using: opioids, enzyme-inducing medications, sleep aids, or excessive alcohol consumption\n* History of mechanical ventilation (\\>24h)\n* Cognitive impairment\n* Operation within 6 months\n* Participate in other clinical trials in the last four weeks\n* Pregnant or breastfeeding",{"count":163,"type":21},20,"Ventilator-associated brain injury (VABI) frequently occurs in ICU patients. Although animal studies indicate the hippocampus as a key target of VABI, its relevance in human patients remains uncertain. In this study, the investigators aim to monitor hippocampal EEG activity during the weaning process of patients off mechanical ventilation, and also exploring the coupling between breathing patterns and hippocampal activity.",[166,167],"Mechanical Ventilation Complication","Brain Injuries",[169,170,171],"Ventilator Associated Brain Injury","Hippocampus Oscillation","Mechanical Ventilation","2024-08-06",{"date":174,"type":41},"2024-08-09",{"date":176,"type":41},"2024-05-08",{"date":178,"type":21},"2025-06-01",{"name":47,"class":48},""]